Girdhar M. Taori

Girdhar M. Taori

Auto-generated profile, based on publicly available information

Girdhar M. Taori

Biochemistry Research Laboratory, Central India Institute of Medical Sciences, Nagpur, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of Infection
Verified
Journal Article
Closed access
JSJitendra Singh
Jitendra Singh
MSManimuthu Mani Sankar
Manimuthu Mani Sankar
PKParveen Kumar
Parveen Kumar
DCDavid Couvin
David Couvin
NRNalin Rastogi
Nalin Rastogi
SSSoumya Swaminathan
Soumya Swaminathan

7 August 2009 in Infection
Verified
Journal Article
Closed access
PDF file
RKR. S. Kashyap
R. S. Kashyap
SRS. S. Ramteke
S. S. Ramteke
SMS. H. Morey
S. H. Morey
HPHemant Purohit
Hemant Purohit
GTG. M. Taori
G. M. Taori
HDH. F. Daginawala
H. F. Daginawala

23 April 2014 in Neuroimmunomodulation
Verified
Journal Article
Closed access
PDF file
RKRajpal Singh Kashyap
Rajpal Singh Kashyap
SMShweta Morey
Shweta Morey
SBShradha Bhullar
Shradha Bhullar
NBNeeraj Baheti
Neeraj Baheti
NCNitin Chandak
Nitin Chandak
HDHatim Daginawala
Hatim Daginawala
Background: Chikungunya infection caused by Chikungunya virus (CHIKV) is an inflammatory disease affecting the joints and may also lead to neurological complications. We investigated a panel of human Toll-like receptor (TLR)-induced cytokines in Chikungunya patients with and without neurological complications. Methods: In a case-control study, a panel of 12 cytokines and chemokines, TNF-α, IFN-α, IL-1β, IL-6, IL-12, IL-17A, IL-8, monocyte chemotactic protein (MCP)-1, RANTES, interferon (IFN)-γ-induced protein (IP)-10, monokine induced by IFN-γ (MIG) and thymus and activation-regulated chemokine (TARC), was analysed using a conventional ELISA protocol in the serum samples of Chikungunya patients without neurological complications and in the cerebrospinal fluid (CSF) and paired serum samples of Chikungunya patients with neurological complications. Results: The levels of 3 cytokines, IL-1β, IL-17A and IL-8, and 4 chemokines, MCP-1, RANTES, IP-10 and TARC, were raised in serum samples of Chikungunya patients without neurological complications, whereas, 4 cytokines, TNF-α, IFN-α, IL-6 and IL-8, and 4 chemokines, MCP-1, RANTES, MIG and TARC, were elevated in CSF samples of Chikungunya patients with neurological complications. Moreover, the levels of IL-6 and IL-8 cytokines were significantly elevated in the CSF compared to paired serum samples in Chikungunya patients with neurological complications. Conclusions: In CHIKV infection, multiple cytokines are elevated in serum and CSF. The elevation in IL-6 and IL-8 cytokines in CSF correlates with neurological involvement.

1 January 2015 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
SWShubhangi R. Warke
Shubhangi R. Warke
DKDewanand R. Kalorey
Dewanand R. Kalorey
HDHatim F. Daginawala
Hatim F. Daginawala
GTGirdhar M. Taori
Girdhar M. Taori
RKRajpal S. Kashyap
Rajpal S. Kashyap
Husain AA, et al. Clin Exp Vaccine Res. 2015 Jan;4(1):83-87. https://doi.org/10.7774/cevr.2015.4.1.83

16 September 2015 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
HDHatim F. Daginawala
Hatim F. Daginawala
SWShubhangi R. Warke
Shubhangi R. Warke
DKDewanand R. Kalorey
Dewanand R. Kalorey
NKNitin V. Kurkure
Nitin V. Kurkure
RKRajpal S. Kashyap
Rajpal S. Kashyap
Limited experimental evidences are available on the use of peptides as vaccines to boost BCG induced immunity for protection against tuberculosis. The present study therefore evaluated protective efficacy of booster dose of N-terminal peptides of Ag85B, using prime boost approaches in murine model of tuberculosis. Using earlier established subcutaneous murine model of TB in our laboratory, we compared the protective vaccination efficacy of peptides of Ag85B with that of booster dose of whole Ag85B and BCG by evaluating both antibody and cell-mediated immune response. Groups of mice primed by BCG and boosted with Ag85B peptides showed limited pulmonary bacillary burden and reduced lung pathology after challenge with virulent dose of Mycobacterium tuberculosis in mice. Significant levels (p < 0.001) of BCG specific antibodies (anti-BCG, anti-PPD) and T cell-specific cytokines were observed in Ag85B peptides boosted mice compared to Ag85B and BCG. Ag85B and BCG boosted mice however showed significant protection compared to single BCG dose and unvaccinated control groups. Our result suggests that prime boost strategy using N-terminal peptides of Ag85B may improve immunogenicity of BCG against TB. Such peptides may be attractive candidates for boosting waning BCG induced immune response in near future. However study demands further work including improvisation in experimental designs to justify the results.